Perrigo Company plc
General ticker "PRGO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.7B (TTM average)
Perrigo Company plc does not follow the US Stock Market performance with the rate: -25.2%.
Estimated limits based on current volatility of 2.7%: low 10.37$, high 10.95$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-05-29, amount 0.29$ (Y11.09%)
- Total employees count: 8379 (-8.3%) as of 2024
- US accounted for 60.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Market competition, Regulatory and compliance, Economic downturns and volatility, Supply chain disruptions
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.25$, 18.74$]
- 2026-12-31 to 2027-12-31 estimated range: [8.61$, 17.10$]
Financial Metrics affecting the PRGO estimates:
- Positive: with PPE of 5.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 6.59 < Operating cash flow per share per price, % of 12.63
- Negative: Inventory ratio change, % of 1.44 > 0.78
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: 19.24 < Shareholder equity ratio, % of 34.39 <= 42.59
- Negative: negative Industry operating cash flow (median)
Short-term PRGO quotes
Long-term PRGO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4,655.60MM | $4,373.40MM | $4,253.10MM |
| Operating Expenses | $4,503.70MM | $4,260.50MM | $5,375.30MM |
| Operating Income | $151.90MM | $112.90MM | $-1,122.20MM |
| Non-Operating Income | $-160.20MM | $-193.60MM | $-175.70MM |
| Interest Expense | $173.80MM | $187.80MM | $162.50MM |
| R&D Expense | $122.50MM | $112.20MM | $95.40MM |
| Income(Loss) | $-8.30MM | $-80.70MM | $-1,297.90MM |
| Taxes | $-3.90MM | $80.00MM | $104.40MM |
| Other Income(Loss) | $-8.30MM | $-11.10MM | $-23.10MM |
| Net Income(Loss)* | $-21.00MM | $-182.90MM | $-1,425.40MM |
| Stockholders Equity | $4,767.90MM | $4,319.40MM | $2,935.50MM |
| Inventory | $1,140.90MM | $1,081.80MM | $1,149.00MM |
| Assets | $10,809.10MM | $9,647.70MM | $8,535.20MM |
| Operating Cash Flow | $405.50MM | $362.90MM | $238.50MM |
| Capital expenditure | $101.70MM | $118.30MM | $93.40MM |
| Investing Cash Flow | $-77.50MM | $78.80MM | $-75.40MM |
| Financing Cash Flow | $-187.20MM | $-611.00MM | $-220.50MM |
| Earnings Per Share** | $-0.16 | $-1.33 | $-10.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.